{"id":3334,"date":"2025-03-24T14:15:34","date_gmt":"2025-03-24T11:15:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3334"},"modified":"2025-03-24T14:26:43","modified_gmt":"2025-03-24T11:26:43","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/ar\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk\/","title":{"rendered":"Entrada Therapeutics \u064a\u062d\u0635\u0644 \u0639\u0644\u0649 \u062a\u0631\u062e\u064a\u0635 \u0641\u064a \u0627\u0644\u0645\u0645\u0644\u0643\u0629 \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0644\u0628\u062f\u0621 ELEVATE-45-201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 Entrada Therapeutics \u0639\u0646 \u062d\u0635\u0648\u0644\u0647\u0627 \u0639\u0644\u0649 \u062a\u0631\u062e\u064a\u0635 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u062a\u0646\u0638\u064a\u0645 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0648\u0645\u0646\u062a\u062c\u0627\u062a \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u0635\u062d\u064a\u0629 \u0641\u064a \u0627\u0644\u0645\u0645\u0644\u0643\u0629 \u0627\u0644\u0645\u062a\u062d\u062f\u0629 (MHRA) \u0648\u0644\u062c\u0646\u0629 \u0623\u062e\u0644\u0627\u0642\u064a\u0627\u062a \u0627\u0644\u0628\u062d\u062b \u0644\u0628\u062f\u0621 \u062a\u062c\u0631\u0628\u0629 ELEVATE-45-201. ELEVATE-45-201 \u0647\u064a \u062f\u0631\u0627\u0633\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 1\/2 \u0644\u0644\u062c\u0631\u0639\u0629 \u0627\u0644\u0645\u062a\u0635\u0627\u0639\u062f\u0629 \u0627\u0644\u0645\u062a\u0639\u062f\u062f\u0629 (MAD) \u0644\u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u0645\u0646\u062a\u062c \u0627\u0644\u0637\u0628\u064a \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a ENTR-601-45 \u0645\u0646 Entrada \u0644\u0639\u0644\u0627\u062c \u0636\u0645\u0648\u0631 \u0627\u0644\u0639\u0636\u0644\u0627\u062a \u062f\u0648\u0634\u064a\u0646 (DMD) \u0627\u0644\u0645\u062d\u062a\u0645\u0644 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0637\u0641\u0631\u0629 \u0645\u0624\u0643\u062f\u0629 \u0641\u064a \u062c\u064a\u0646 DMD \u0642\u0627\u0628\u0644\u0629 \u0644\u062a\u062e\u0637\u064a \u0627\u0644\u0625\u0643\u0633\u0648\u0646 45.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u064a\u062a\u0639\u0644\u0645 \u0623\u0643\u062b\u0631: <a href=\"https:\/\/dmdwarrior.com\/ar\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" data-type=\"post\" data-id=\"1445\" rel=\"noreferrer noopener\">\u0645\u0627 \u0647\u0648 \u062a\u062e\u0637\u064a \u0627\u0644\u0625\u0643\u0633\u0648\u0646\u061f<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics, announced it has received authorization from the United Kingdom\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1\/2 multiple ascending dose (MAD) clinical study to evaluate Entrada\u2019s investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3335,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[320,321,234,317,318,319,48,322],"class_list":["post-3334","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-45-201","tag-entr-601-45","tag-entrada-therapeutics","tag-exon-45","tag-exon-45-skipping","tag-exon-45-skipping-therapy","tag-uk","tag-united-kingdom"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/posts\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/comments?post=3334"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/posts\/3334\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/media\/3335"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/media?parent=3334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/categories?post=3334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/ar\/wp-json\/wp\/v2\/tags?post=3334"}],"curies":[{"name":"\u0648\u0648\u0631\u062f\u0628\u0631\u064a\u0633","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}